Coeptis Therapeutics Inc COEP:OTCPK

RT Quote | Exchange | USD
Last | 3:58 PM EDT
2.35quote price arrow up+0.35 (+17.50%)
Volume
7,521
52 week range
1.65 - 14.00
Loading...
  • Open1.90
  • Day High2.35
  • Day Low1.90
  • Prev Close2.00
  • 52 Week High14.00
  • 52 Week High Date01/11/22
  • 52 Week Low1.65
  • 52 Week Low Date09/23/22

Key Stats

  • Market Cap91.67M
  • Shares Out39.01M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta-1.19
  • YTD % Change-41.98

KEY STATS

  • Open1.90
  • Day High2.35
  • Day Low1.90
  • Prev Close2.00
  • 52 Week High14.00
  • 52 Week High Date01/11/22
  • 52 Week Low1.65
  • 52 Week Low Date09/23/22
  • Market Cap91.67M
  • Shares Out39.01M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta-1.19
  • YTD % Change-41.98

RATIOS/PROFITABILITY

  • EPS (TTM)-1.02
  • P/E (TTM)-2.31
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-34.317M
  • ROE (TTM)-1,166.49%
  • Revenue (TTM)0.00
  • Gross Margin (TTM)100.00%
  • Net Margin (TTM)-17,932.39%
  • Debt To Equity (MRQ)184.99%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Coeptis Therapeutics Inc

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Coeptis Therapeutics, Inc. is a biopharmaceutical company. The Company, through its subsidiary, Coeptis Pharmaceuticals, Inc., is engaged in developing cell therapy platforms for cancer. Its product portfolio comprises CD38-GEAR-NK and CD38-Diagnostic. The Company's CD38-GEAR-NK is an autologous, natural killer (NK) cell-based therapeutic that is derived from a patient’s own cells and gene-edited to enable combination therapy with anti-CD38 monoclonal antibodies (mAbs). Its...
David Mehalick
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Christine Sheehy
Chief Financial Officer, Secretary, Director
Address
105 Bradford Rd, Suite 420
Wexford, PA
15090
United States